Attapon Cheepsattayakorn1,2*, Ruangrong Cheepsattayakorn3 and Porntep Siriwanarangsun1
1Faculty of Medicine, Western University, Pathumtani Province, Thailand
210th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand
3Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.
Received: February 18, 2022; Published: March 01, 2022
The Omicron variant (BA.1/B.1.1.529) is characterized by mutation of an unusually high number, with 26 to 32 changes (up to 36 mutations) in the spike (S) glycoprotein [1-3], the key epitopes (target) of neutralizing antibodies [2,3]. A recent study revealed that the Omicron variant is more likely to cause reinfection than previous SARS-CoV-2 variants, indicating some immune-escape levels . Recently, neutralization potency of sera mRNA-1273, BNT162b2, and Ad26.COV2.S vaccine recipients against wild-type, Delta, and Omicron SARS-CoV-2 pseudoviruses was studied and demonstrated potent neutralization of Omicron variant and 4-6-fold lower than the wild type among mRNA vaccinated individuals, indicating enhanced cross-reactivity of neutralizing antibody responses [2,4]. Polyclonal sera from persons vaccinated with two doses of the BNT162b2 COVID-19 vaccine and from convalescent persons showed a near-complete lack of neutralizing activity against Omicron variant, as well as different monoclonal-antibodies resistance in clinical application [2,3].
Citation: Attapon Cheepsattayakorn., et al. “COVID-19 Vaccine Boosters Inducing Neutralizing Immunity Against SARS-CoV-2 Omicron Variant”. Acta Scientific Microbiology 5.4 (2022): 01.
Copyright: © 2022 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.